Comparison of the Clinical Characteristics of Bisphosphonate-associated Osteonecrosis of the Jaw with Inflammation-associated Osteonecrosis of the Jaw in Patients with Osteoporosis and Benign Diseases
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: Osteonecrosis of the jaw (ONJ) involving the use of bisphosphonates is referred to as bisphosphonate-associated ONJ (BONJ). Inflammation also can cause ONJ and it may be called inflammation-associated ONJ (IONJ). The aim of this study was to compare clinical characteristics between BONJ and IONJ. Materials and Methods: Medical records at the Ajou University Hospital were reviewed using key words “osteonecrosis”, “sequestrum”, and “dead bone” of the mandible and maxilla. Eighteen patients diagnosed with ONJ were identified from January 2003 to December 2009. Using criteria from the American Association of Oral and Maxillofacial Surgeons, 12 cases were diagnosed as BONJ and six as IONJ. Clinical characteristics and treatment modalities, outcomes of two groups of patients were investigated. Results: Patients of the BONJ group were older than those of IONJ group (median: 76.5 years vs. 60 years). In the BONJ group, mandible was more commonly involved sites and percentage of diabetic patients was higher. Three of 12 (25%) BONJ patients received oral glucocorticoids, while none of the IONJ patients. Ten (83.3%) of the BONJ cases and 2 (33.3%) of the IONJ cases were triggered by dental extractions. Though duration of ONJ treatment was longer in the BONJ group than the IONJ group (6.4±5.2 months vs. 2.9±1.9 months), both groups eventually showed good prognosis. Conclusions: ONJ may occur in the absence of bisphosphonate. BONJ occurred in older patients, and needed longer treatment duration compared to IONJ. Prognosis of ONJ was relatively good.
Abstract
Objectives: Osteonecrosis of the jaw (ONJ) involving the use of bisphosphonates is referred to as bisphosphonate-associated ONJ (BONJ). Inflammation also can cause ONJ and it may be called inflammation-associated ONJ (IONJ). The aim of this study was to compare clinical characteristics between BONJ and IONJ. Materials and Methods: Medical records at the Ajou University Hospital were reviewed using key words “osteonecrosis”, “sequestrum”, and “dead bone” of the mandible and maxilla. Eighteen patients diagnosed with ONJ were identified from January 2003 to December 2009. Using criteria from the American Association of Oral and Maxillofacial Surgeons, 12 cases were diagnosed as BONJ and six as IONJ. Clinical characteristics and treatment modalities, outcomes of two groups of patients were investigated. Results: Patients of the BONJ group were older than those of IONJ group (median: 76.5 years vs. 60 years). In the BONJ group, mandible was more commonly involved sites and percentage of diabetic patients was higher. Three of 12 (25%) BONJ patients received oral glucocorticoids, while none of the IONJ patients. Ten (83.3%) of the BONJ cases and 2 (33.3%) of the IONJ cases were triggered by dental extractions. Though duration of ONJ treatment was longer in the BONJ group than the IONJ group (6.4±5.2 months vs. 2.9±1.9 months), both groups eventually showed good prognosis. Conclusions: ONJ may occur in the absence of bisphosphonate. BONJ occurred in older patients, and needed longer treatment duration compared to IONJ. Prognosis of ONJ was relatively good.
참고문헌 (26)
- Marx RE, "Pamidronate (Aredia) and zoledronate(Zometa) induced avascular necrosis of the jaws: Agrowing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)
- Wang J, "Osteonecrosis of the jaws associated with chemotherapy", J Oral Maxillofac Surg, 61, pp.1104~1107 (2003)
- Bouquot JE, "Alveolar osteonecrosis", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 84, pp.229~230 (1997)
- Almazrooa SA, "Bisphosphonate and nonbisphosphonate- associated osteonecrosis of the jaw: a review", J Am Dent Assoc, 140, pp.864~875 (2009)
- Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, "American Association of Oral and Maxillofacial SurgeonsPosition paper on bisphosphonate-related osteonecrosis of the jaws", J Oral Maxillofac Surg, 65, pp.369~376 (2007)
- Durie BG, "Osteonecrosis of the jaw and bisphosphonates", N Engl J Med, 353, pp.99~102 (2005)
- Bamias A, "Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors", J Clin Oncol, 23, pp.8580~8587 (2005)
- Hoff AO, "Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates", J Bone Miner Res, 23, pp.826~836 (2008)
- Hong JW, "Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia", Osteoporos Int, 21, pp.847~853 (2010)
- Marx RE, "Oral bisphosphonateinduced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment", J Oral Maxillofac Surg, 65, pp.2397~2410 (2007)
- Favia G, "Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients", J Rheumatol, 36, pp.2780~2787 (2009)
- Thumbigere-Math V, "Bisphosphonaterelated osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients", J Oral Maxillofac Surg, 67, pp.1904~1913 (2009)
- Stanton DC, "Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases", J Oral Maxillofac Surg, 67, pp.943~950 (2009)
- Yarom N, "Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome", Osteoporos Int, 18, pp.1363~1370 (2007)
- Khosla S, "Bisphosphonateassociated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 22, pp.1479~1491 (2007)
- Shiau HJ, "Sex differences in destructive periodontal disease: a systemic review", J Periodontol, 81, pp.1379~1389 (2010)
- Marx RE, "Osteoradionecrosis: A new concept of its pathophysiology", J Oral Maxillofac Surg, 41, pp.283~288 (1983)
- Marx RE, "A new concept in the treatment of osteoradionecrosis", J Oral Maxillofac Surg, 41, pp.351~357 (1983)
- Greuter S, "Bevacizumab-associated osteonecrosis of the jaw", Ann Oncol, 19, pp.2091~2092 (2008)
- Brunello A, "Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma", Bone, 44, pp.173~175 (2009)
- Mashiba T, "Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib", J Bone Miner Res, 15, pp.613~620 (2000)
- Fournier P, "Bisphophonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats", Cancer Res, 62, pp.6538~6544 (2002)
- Reid IR, "Is bisphosphonateassociated osteonecrosis of the jaw caused by soft tissue toxicity?", Bone, 41, pp.318~320 (2007)
- Van den Wyngaert T, "Osteonecrosis of the jaw related to the use of bisphosphonates", Curr Opin Oncol, 19, pp.315~322 (2007)
- Marx RE, "Bisphosphonate-induced exposed bone (osteonecrosis", osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment, 2005, pp.63, 1567~1575
- Ruggiero SL, "Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases", J Oral Maxillofac Surg, 62, pp.527~534 (2004)